DRW8 Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. In addition, it offers patient monitoring systems; anaesthesia machines; medical ventilators and lung monitoring; neonatal incubators and thermoregulation; phototherapy lights and bilirubinometers; surgical and examination lights; medical pendants and infrastructure design; medical gas pipeline system in hospitals; and hospital consumables and accessories, as well as hospital planning and design services. Further, the company offers alcohol and drug testing; diving equipment; fixed gas detectors; hazmat suits; portable gas detection; head and eye protection; rescue and escape; respiratory protection; safety-training systems; thermal imaging cameras; and workshop solution and breathing gas supply, as well as provides various training and services. The company was founded in 1889 and is headquartered in Lübeck, Germany. Drägerwerk AG & Co. KGaA operates as a subsidiary of Dr. Heinrich Dräger GmbH.…
Industry Peers
Medical DevicesKey Statistics
About Drägerwerk (ETR: DRW8)
›
Drägerwerk (ETR: DRW8) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 16,716 employees.
The shares were at 89.00 EUR on 19 November 2026, up 45.9% over 52 weeks. Its 52-week range is 55.60 EUR to 96.00 EUR: the price is 7.3% below the high and 60.1% above the low.
At a market capitalisation of 1.67B EUR, it trades at 9.9 times trailing earnings and 12.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 61% for DRW8. It pays a dividend yielding 2.66% (it pays out 25% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Drägerwerk reports return on equity of 8.6%, an operating margin of 7.1% and revenue up 2.1% year over year.
Its debt exceeds its cash by 92.17M EUR, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 89.00 EUR is 0.0% above the current price.